News

These tablets are the generic version of US-based pharmaceutical firm Warner Chilcott’s Generess Fe tablets. The US Food and Drug Administration (FDA) has also granted final approval for

The Phase II acne vulgaris trial will be conducted at about ten sites in Australia and New Zealand with Dr Lynda Spelman as the principal investigator. The trial

The drug sponsor, MultiCorp International, has retained Compass Point to manage the product development program. Under the deal, NDA Partners will provide the drug development and regulatory expertise

The agreement allows the alliance to establish a combined oncology sales organization in key markets in advance of the potential launch of avelumab-based treatment regimens in the future.

As part of the deal, Neurotrope will pay WCT about $300,000 for the services and related third-party costs. In early second quarter of 2015, Neurotrope plans to submit

RTOG Foundation’s partner NRG Oncology will be responsible for conducting the pivotal Phase II/III anal cancer trial of concurrent chemotherapy of mitomycin C/5FU and radiation therapy (CCRT) compared

If approved, this will become the fourth indication for Pradaxa (dabigatran etexilate mesylate). The sNDA is based on the results of two randomized, double-blind Phase III trials, RE-NOVATE

As part of the deal, Sanofi Pasteur will have an option to acquire certain worldwide rights to use VBI’s LPV technology in its vaccines to provide improved stability.

Data from this trial supported the initiation of the ongoing, pivotal Phase II METRIC trial in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab